Latest & greatest articles for prostate cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on prostate cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on prostate cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for prostate cancer

21. Managing prostate cancer during COVID-19 : CUOG/CUA

Managing prostate cancer during COVID-19 : CUOG/CUA Flipbook To view this page ensure that Adobe Flash Player version 10.0.0 or greater is installed. Besides, it's possible to , or you can view flippdf Either scripts and active content are not permitted to run or Adobe Flash Player version 10.0.0 or greater is not installed. Besides, it's possible to , or you can view flippdf

2020 Canadian Urological Association

22. Differential Impact of Gonadotropin-releasing Hormone Antagonist Versus Agonist on Clinical Safety and Oncologic Outcomes on Patients with Metastatic Prostate Cancer: A Meta-analysis of Randomized Controlled Trials

Differential Impact of Gonadotropin-releasing Hormone Antagonist Versus Agonist on Clinical Safety and Oncologic Outcomes on Patients with Metastatic Prostate Cancer: A Meta-analysis of Randomized Controlled Trials Differential Impact of Gonadotropin-releasing Hormone Antagonist Versus Agonist on Clinical Safety and Oncologic Outcomes on Patients with Metastatic Prostate Cancer: A Meta-analysis of Randomized Controlled Trials - PubMed This site needs JavaScript to work properly. Please enable (...) Actions . 2020 Jun 27;S0302-2838(20)30429-2. doi: 10.1016/j.eururo.2020.06.002. Online ahead of print. Differential Impact of Gonadotropin-releasing Hormone Antagonist Versus Agonist on Clinical Safety and Oncologic Outcomes on Patients with Metastatic Prostate Cancer: A Meta-analysis of Randomized Controlled Trials , , , , , , , , , Affiliations Expand Affiliations 1 Department of Special Surgery, Jordan University Hospital, The University of Jordan, Amman, Jordan; The National Center for Diabetes

2020 EvidenceUpdates

23. Addition of Androgen-Deprivation Therapy or Brachytherapy Boost to External Beam Radiotherapy for Localized Prostate Cancer: A Network Meta-Analysis of Randomized Trials

Addition of Androgen-Deprivation Therapy or Brachytherapy Boost to External Beam Radiotherapy for Localized Prostate Cancer: A Network Meta-Analysis of Randomized Trials Addition of Androgen-Deprivation Therapy or Brachytherapy Boost to External Beam Radiotherapy for Localized Prostate Cancer: A Network Meta-Analysis of Randomized Trials - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History (...) for external citation management software Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Share Permalink Copy Page navigation J Clin Oncol Actions . 2020 May 12;JCO1903217. doi: 10.1200/JCO.19.03217. Online ahead of print. Addition of Androgen-Deprivation Therapy or Brachytherapy Boost to External Beam Radiotherapy for Localized Prostate Cancer: A Network Meta-Analysis of Randomized Trials

2020 EvidenceUpdates

24. Darolutamide (Nubeqa) - non-metastatic castration-resistant prostate cancer (nmCRPC)

Darolutamide (Nubeqa) - non-metastatic castration-resistant prostate cancer (nmCRPC) Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related to the original authorization of a product. The for is located below. Recent Activity for SBDs written

2020 Health Canada - Drug and Health Product Register

25. TULSA-PRO system - prostate cancer

TULSA-PRO system - prostate cancer Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) Summary basis of decision (SBD) documents provide information related to the original authorization of a product. The for the is located below. Updated: The following table describes post

2020 Health Canada - Drug and Health Product Register

26. Clinical Practice Guidelines – Prostate Cancer

Clinical Practice Guidelines – Prostate Cancer Prostate Cancer | ESMO Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly. MINIMAL Requirements: , , , , , Search Clinical Practice Guidelines – Prostate Cancer Published in 2020 – Ann Oncol (2020) Authors: C. Parker, E. Castro, K. Fizazi, A. Heidenreich, P. Ost, G. Procopio, B. Tombal & S. Gillessen Prostate cancer is reported as the second most common cancer in men. The updated (...) ESMO Clinical Practice Guidelines on prostate cancer provide information on the current management of prostate cancer including recommendations for screening and diagnosis, along with stage-matched therapeutic strategies. Related items Read full article Legal Useful links Subscribe to ESMO newsletters Receive information and updates on ESMO’s scientific and educational resources, events, members activities. To sign up for ESMO newsletters, and select the newsletters you’d like to receive. ESMO

2020 European Society for Medical Oncology

27. Prostate cancer screening with the PSA test

screening 24 April 2020 Institute for Quality and Efficiency in Health Care (IQWiG) - 1 - 1 Background Prostate cancer is a malignant change in the prostate; as it progresses, it can infiltrate directly adjacent tissue (seminal vesicle, urinary bladder, large intestine) and can form distant metastases. As measured by the number of new cases, prostate cancer is the most common tumour disease in men in Germany, making up 23.0% of all cancer cases. For 2016, the Robert Koch Institute estimated that about (...) 58 780 men received an initial diagnosis of prostate cancer [1]. Age is considered the most important risk factor for the development of prostate cancer [1, 2]. At a median age of onset of 72 years, prostate cancer occurs predominantly in advanced age; it is rarely found before the 45 th to 50 th year of life [1]. Every year, about 14 000 men in Germany die of the consequences of prostate cancer [1]. The prognosis of the disease decisively depends on the tumour stage as well as tumour typing

2020 Institute for Quality and Efficiency in Healthcare (IQWiG)

28. Radical prostatectomy versus deferred treatment for localised prostate cancer. (Abstract)

, AUA, and ASCO) until 3 March 2020.We included all randomised controlled trials (RCTs) that compared RP versus deferred treatment in patients with localised prostate cancer, defined as T1-2, N0, M0 prostate cancer.Two review authors independently assessed the eligibility of references and extracted data from included studies. The primary outcome was time to death from any cause; secondary outcomes were: time to death from prostate cancer; time to disease progression; time to metastatic disease (...) cancer per 1000 men in the RP group compared with 316 deaths from prostate cancer per 1000 men in the WW group. RP may reduce the risk of progression (HR 0.43, 95% CI 0.35-0.54; 2 studies with 1426 participants; I² = 54%; low-certainty evidence); at 19.5 years, this corresponds to 391 progressions per 1000 men for the RP group compared with 684 progressions per 1000 men for the WW group) and probably reduces the risk of developing metastatic disease (HR 0.56, 95% CI 0.46-0.70; 2 studies with 1426

2020 Cochrane

29. Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer. (Abstract)

Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer. Injectable luteinizing hormone-releasing hormone agonists (e.g., leuprolide) are the standard agents for achieving androgen deprivation for prostate cancer despite the initial testosterone surge and delay in therapeutic effect. The efficacy and safety of relugolix, an oral gonadotropin-releasing hormone antagonist, as compared with those of leuprolide are not known.In this phase 3 trial, we randomly assigned patients (...) with advanced prostate cancer, in a 2:1 ratio, to receive relugolix (120 mg orally once daily) or leuprolide (injections every 3 months) for 48 weeks. The primary end point was sustained testosterone suppression to castrate levels (<50 ng per deciliter) through 48 weeks. Secondary end points included noninferiority with respect to the primary end point, castrate levels of testosterone on day 4, and profound castrate levels (<20 ng per deciliter) on day 15. Testosterone recovery was evaluated in a subgroup

2020 NEJM

30. Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer. (Abstract)

Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer. Preliminary trial results showed that enzalutamide significantly improved metastasis-free survival among men who had nonmetastatic, castration-resistant prostate cancer and rapidly increasing prostate-specific antigen (PSA) levels while taking androgen-deprivation therapy. Results from the final analysis of overall survival have not yet been reported.In this double-blind, phase 3 trial, men with nonmetastatic (...) , castration-resistant prostate cancer (defined on the basis of conventional imaging and a PSA doubling time of ≤10 months) who were continuing to receive androgen-deprivation therapy were randomly assigned (in a 2:1 ratio) to receive enzalutamide at a dose of 160 mg or placebo once daily. Overall survival was assessed with a group sequential testing procedure and an O'Brien-Fleming-type alpha-spending function.As of October 15, 2019, a total of 288 of 933 patients (31%) in the enzalutamide group and 178

2020 NEJM

31. The EAU – EANM – ESTRO – ESUR – SIOG Guidelines on Prostate Cancer

. Association of male circumcision with risk of prostate cancer: a meta-analysis. Prostate Cancer Prostatic Dis, 2015. 18: 352. 73. Rider, J.R., et al. Ejaculation Frequency and Risk of Prostate Cancer: Updated Results with an Additional Decade of Follow-up. Eur Urol, 2016. 70: 974. 74. Brierley, J.D., et al., TNM classification of malignant tumors. UICC International Union Against Cancer. 8th edn. 2017. 75. Cooperberg, M.R., et al. The University of California, San Francisco Cancer of the Prostate Risk (...) of atypical small acinar proliferation. Can J Urol, 2017. 24: 8714. 219. Epstein, J.I., et al. Prostate needle biopsies containing prostatic intraepithelial neoplasia or atypical foci suspicious for carcinoma: implications for patient care. J Urol, 2006. 175: 820. 220. Merrimen, J.L., et al. Multifocal high grade prostatic intraepithelial neoplasia is a significant risk factor for prostatic adenocarcinoma. J Urol, 2009. 182: 485. 221. Kronz, J.D., et al. High-grade prostatic intraepithelial neoplasia

2020 European Association of Nuclear Medicine

32. Effect of Enzalutamide plus Androgen Deprivation Therapy on Health-related Quality of Life in Patients with Metastatic Hormone-sensitive Prostate Cancer: An Analysis of the ARCHES Randomised, Placebo-controlled, Phase 3 Study Full Text available with Trip Pro

for confirmed deterioration for pain outcomes). Enzalutamide delays deterioration in several HRQoL subscales and pain severity in high-volume disease. Conclusions: Enzalutamide plus ADT enables men with mHSPC to maintain high-functioning HRQoL and low symptom burden. Patient summary: This study examined the effect on health-related quality of life and pain of adding enzalutamide or placebo to androgen deprivation therapy for patients with metastatic hormone-sensitive prostate cancer. Addition (...) Effect of Enzalutamide plus Androgen Deprivation Therapy on Health-related Quality of Life in Patients with Metastatic Hormone-sensitive Prostate Cancer: An Analysis of the ARCHES Randomised, Placebo-controlled, Phase 3 Study Effect of Enzalutamide Plus Androgen Deprivation Therapy on Health-related Quality of Life in Patients With Metastatic Hormone-sensitive Prostate Cancer: An Analysis of the ARCHES Randomised, Placebo-controlled, Phase 3 Study - PubMed This site needs JavaScript to work

2020 EvidenceUpdates

33. The Oral Gonadotropin-releasing Hormone Receptor Antagonist Relugolix as Neoadjuvant/Adjuvant Androgen Deprivation Therapy to External Beam Radiotherapy in Patients with Localised Intermediate-risk Prostate Cancer: A Randomised, Open-label, Parallel-group Full Text available with Trip Pro

The Oral Gonadotropin-releasing Hormone Receptor Antagonist Relugolix as Neoadjuvant/Adjuvant Androgen Deprivation Therapy to External Beam Radiotherapy in Patients with Localised Intermediate-risk Prostate Cancer: A Randomised, Open-label, Parallel-group The Oral Gonadotropin-releasing Hormone Receptor Antagonist Relugolix as Neoadjuvant/Adjuvant Androgen Deprivation Therapy to External Beam Radiotherapy in Patients With Localised Intermediate-risk Prostate Cancer: A Randomised, Open-label (...) Gonadotropin-releasing Hormone Receptor Antagonist Relugolix as Neoadjuvant/Adjuvant Androgen Deprivation Therapy to External Beam Radiotherapy in Patients With Localised Intermediate-risk Prostate Cancer: A Randomised, Open-label, Parallel-group Phase 2 Trial , , , , , , , , , , , , , , Affiliations Expand Affiliations 1 The Institute of Cancer Research and Royal Marsden Hospital, London, UK. Electronic address: david.dearnaley@icr.ac.uk. 2 Urology San Antonio, San Antonio, TX, USA. 3 21st Century

2020 EvidenceUpdates

34. External Validation of the 2019 Briganti Nomogram for the Identification of Prostate Cancer Patients Who Should Be Considered for an Extended Pelvic Lymph Node Dissection

External Validation of the 2019 Briganti Nomogram for the Identification of Prostate Cancer Patients Who Should Be Considered for an Extended Pelvic Lymph Node Dissection External Validation of the 2019 Briganti Nomogram for the Identification of Prostate Cancer Patients Who Should Be Considered for an Extended Pelvic Lymph Node Dissection - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History (...) a file for external citation management software Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Share Permalink Copy Page navigation Eur Urol Actions . 2020 Apr 5;S0302-2838(20)30198-6. doi: 10.1016/j.eururo.2020.03.023. Online ahead of print. External Validation of the 2019 Briganti Nomogram for the Identification of Prostate Cancer Patients Who Should Be Considered for an Extended Pelvic Lymph Node Dissection

2020 EvidenceUpdates

35. Olaparib for Metastatic Castration-Resistant Prostate Cancer. (Abstract)

Olaparib for Metastatic Castration-Resistant Prostate Cancer. Multiple loss-of-function alterations in genes that are involved in DNA repair, including homologous recombination repair, are associated with response to poly(adenosine diphosphate-ribose) polymerase (PARP) inhibition in patients with prostate and other cancers.We conducted a randomized, open-label, phase 3 trial evaluating the PARP inhibitor olaparib in men with metastatic castration-resistant prostate cancer who had disease (...) with metastatic castration-resistant prostate cancer who had disease progression while receiving enzalutamide or abiraterone and who had alterations in genes with a role in homologous recombination repair, olaparib was associated with longer progression-free survival and better measures of response and patient-reported end points than either enzalutamide or abiraterone. (Funded by AstraZeneca and Merck Sharp & Dohme; PROfound ClinicalTrials.gov number, NCT02987543.).Copyright © 2020 Massachusetts Medical

2020 NEJM

36. An Endorsement of the 2018 Guideline on Hypofractionated Radiation Therapy for Localized Prostate Cancer: An ASTRO, ASCO, and AUA Evidence-Based Guideline

be offered as an alternative to conventional fractionation. The task force strongly encourages that these patients be treated as part of a clinical trial or multi-institutional registry. Comment: There is additional RCT evidence to support the recommendation of KQ3B that may increase the quality of evidence for the use of ultrahypofractionation in intermediate-risk disease from low to at least moderate [2]. ENDORSED with comment KQ3C: In men with high-risk prostate cancer receiving EBRT, the task force (...) with the recommendations for information purposes. Guideline Endorsement 3-22 Section 2: Endorsement Methods Overview – April 28, 2020 Page 5 Selection of Guidelines The Radiation Treatment Program, Disease Pathway Management, Ontario GU Cancers Advisory Committee, GU disease site group (DSG) chairs reviewed the ASTRO, ASCO, and AUA evidence-based guideline on hypofractionated radiation therapy for localized prostate cancer and accepted it as potentially useful and relevant to guide practice in Ontario. Assessment

2020 Cancer Care Ontario

37. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. (Abstract)

, randomised study, we recruited men with biopsy-proven prostate cancer and high-risk features at ten hospitals in Australia. Patients were randomly assigned to conventional imaging with CT and bone scanning or gallium-68 PSMA-11 PET-CT. First-line imaging was done within 21 days following randomisation. Patients crossed over unless three or more distant metastases were identified. The primary outcome was accuracy of first-line imaging for identifying either pelvic nodal or distant-metastatic disease (...) Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Conventional imaging using CT and bone scan has insufficient sensitivity when staging men with high-risk localised prostate cancer. We aimed to investigate whether novel imaging using prostate-specific membrane antigen (PSMA) PET-CT might improve accuracy and affect management.In this multicentre, two-arm

2020 Lancet

38. Darolutamide (Nubeqa) - prostate cancer

Darolutamide (Nubeqa) - prostate cancer Official address Domenico Scarlattilaan 6 ? 1083 HS Amsterdam ? The Netherlands An agency of the European Union Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 © European Medicines Agency, 2020. Reproduction is authorised provided the source is acknowledged. EMA/58296/2020 EMEA/H/C/004790 Nubeqa (darolutamide) An overview of Nubeqa and why (...) it is authorised in the EU What is Nubeqa and what is it used for? Nubeqa is a medicine used to treat men with prostate cancer. It is used when the cancer is castration-resistant (worsens despite treatment to lower testosterone levels, including surgical removal of the testes) and is at high risk of metastasis (spreading to other parts of the body). Nubeqa contains the active substance darolutamide. How is Nubeqa used? Nubeqa is available as tablets (300 mg) and can only be obtained with a prescription

2020 European Medicines Agency - EPARs

39. Radical Prostatectomy or Observation for Clinically Localized Prostate Cancer: Extended Follow-up of the Prostate Cancer Intervention Versus Observation Trial (PIVOT) Full Text available with Trip Pro

trial conducted at the US Department of Veterans Affairs and National Cancer Institute sites. The participants were men (n=731) ≤75yr of age with localized prostate cancer, prostate-specific antigen (PSA) <50ng/ml, life expectancy ≥10yr, and medically fit for surgery. Intervention: Radical prostatectomy versus observation. Outcome measurements and statistical analysis: All-cause mortality was assessed in the entire cohort and patient and tumor subgroups. Intention-to-treat analysis was conducted (...) with intermediate-risk disease although not in men with high-risk disease. Patient summary: In this randomized study, we evaluated death from any cause in men with early prostate cancer treated with either surgery or observation. Overall, surgery may provide small very long-term reductions in death from any cause and increases in years of life gained. Absolute effects were much smaller in men with low-risk disease, but were greater in men with intermediate-risk disease although not in men with high-risk disease

2020 EvidenceUpdates

40. The effect of assessing genetic risk of prostate cancer on the use of PSA tests in primary care: A cluster randomized controlled trial Full Text available with Trip Pro

The effect of assessing genetic risk of prostate cancer on the use of PSA tests in primary care: A cluster randomized controlled trial The Effect of Assessing Genetic Risk of Prostate Cancer on the Use of PSA Tests in Primary Care: A Cluster Randomized Controlled Trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Welcome to the new PubMed. For legacy PubMed go to . Clipboard, Search History, and several other advanced (...) citation management software Create file Cancel Actions Cite Share Permalink Copy Page navigation PLoS Med Actions . 2020 Feb 7;17(2):e1003033. doi: 10.1371/journal.pmed.1003033. eCollection 2020 Feb. The Effect of Assessing Genetic Risk of Prostate Cancer on the Use of PSA Tests in Primary Care: A Cluster Randomized Controlled Trial , , , , , , , , Affiliations Expand Affiliations 1 Department of Clinical Medicine, Aarhus University, Aarhus, Denmark. 2 Department of Molecular Medicine, Aarhus

2020 EvidenceUpdates